

CORRECTION

Open Access



Correction to: Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

Chunfeng Xie^{1†}, Xu Zhou^{1†}, Chunhua Liang^{1†}, Xiaoting Li^{1†}, Miaomiao Ge¹, Yue Chen¹, Juan Yin², Jianyun Zhu^{2*} and Caiyun Zhong^{1,3*}

Correction to: *J Exp Clin Cancer Res* 40, 266 (2021)

<https://doi.org/10.1186/s13046-021-02069-4>

Following publication of the original article [1], minor errors were identified in the images presented in Figs. 2, 4, and 5; specifically:

- Fig. 2a: Flow cytometry assay of cell cycle distribution; bottom left panel has been corrected (incorrect 'S' percentage originally displayed)
- Fig. 4a: Wound healing assay for H1299 cells after apatinib treatment for 48h; correct photograph used for Stage 5 (2nd row, 3rd column)
- Fig. 5d: Immunofluorescence staining of p-STAT3 in A549 cells after apatinib treatment; correct photograph used for Stage 2 Merge (3rd row, 2nd column)
- Fig. 5d: Immunofluorescence staining of p-STAT3 in H1299 cells after apatinib treatment; correct photograph used for Stage 5 p-STAT3 (1st row, 3rd column)

The authors provided the journal with the original data files. The corrected figures are given below. The correction does not have any effect on the results or conclusions of the paper. The original article has been corrected.

Author details

¹Department of Nutrition and Food Safety, School of Public Health, Nanjing Medical University, 101 Longmian Ave, Jiangning, Nanjing 211166, China.

²Department of Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 242 Guangji Rd, Suzhou 215008, China. ³Cancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu, China.

Published online: 06 November 2021

Reference

1. Xie C, Zhou X, Liang C, et al. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer. *J Exp Clin Cancer Res*. 2021;40:266. <https://doi.org/10.1186/s13046-021-02069-4>.

The original article can be found online at <https://doi.org/10.1186/s13046-021-02069-4>.

*Correspondence: njmuzhuji@njmu.edu.cn; cyzhong@njmu.edu.cn


[†]Chunfeng Xie, Xu Zhou, Chunhua Liang and Xiaoting Li contributed equally to this work.


²Department of Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 242 Guangji Rd, Suzhou 215008, China

³ Cancer Research Division, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu, China
Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.





(See figure on next page.)

Fig. 5 Apatinib downregulated VEGFR2/STAT3/PD-L1 pathway in NSCLC cells and reduced the immunosuppressive TME. **a** Western blot analysis of VEGFR2 and p-VEGFR2 (Tyr1175) expression and qRT-PCR analysis of VEGFR2 expression in A549 and H1299 cells after apatinib treatment for 48 h. The data are presented as mean ± SD ($n = 3$). ** $p < 0.01$ vs. control. **b** and **c** Western blot analysis of p-STAT3, STAT3, c-Myc and PD-L1 expressions in A549 and H1299 cells after indicated treatment. **d** Immunofluorescence staining of p-STAT3 in A549 and H1299 cells after apatinib treatment for 4 h (p-STAT3: green; DAPI: blue). Scar bar = 50 μm. **e** Western blot analysis of p-STAT3, STAT3 and PD-L1 expressions in A549 and H1299 cells after apatinib treatment with or without pretreatment of IL-6 for 48 h. **f** Western blot and qRT-PCR analysis of PD-L1 expression in THP-1-derived macrophages with or without stimulation with CM from A549 and H1299 cells. The data are presented as mean ± SD ($n = 3$). * $p < 0.05$, ** $p < 0.01$ vs. A549 or H1299-CM control. # $p < 0.05$, ## $p < 0.01$ vs. medium control. **g** and **h** Jurkat cells were activated by stimulation with anti CD3/CD28 antibodies and then co-cultured with non-treated or apatinib (10 μM) pretreated A549 or H1299 cells; the Jurkat cells were collected for CD69 detection by flow cytometry (**g**) and the co-culture medium was collected for IFN-γ secretion by ELISA assay (**h**). The data are presented as mean ± SD ($n = 3$). && $p < 0.01$ vs (-) Jurkat cell only group. ** $p < 0.01$ vs. A549 + Jurkat or H1299 + Jurkat control group. ## $p < 0.01$ vs. Jurkat cells only stimulated with anti CD3/CD28 antibodies group

